different forms of tests, including self-administered and professionally administered tests, and shall include the following: (1) Evaluation of self-administered tests The Director shall institute, on an expedited basis, an evaluation of those promising self-administered test products that have the capacity to provide cost-effective, high volume human testing of either presence of active virus or proof of prior infection and likely immunity or resistance to reinfection. The Director shall establish a network of hospitals and research institutions capable of carrying out these analyses, and shall quickly develop protocols for such testing with a goal of providing useful information within one week and more complete information in two weeks. (2) Evaluation of professionally administered tests The Director shall review information regarding different tests that have been developed that require independent technical personnel and shall conduct such independent evaluations as the Director determines will be helpful to determine those mechanisms that have the greatest potential to contribute to reopening plans. (3) Evaluation of population-level testing The Director shall evaluate the potential and feasibility of population-level testing for contributing to State reopening plans. For purposes of this paragraph, the term population-level testing means testing of significant parts of the population that might be accomplished other than at points of medical care, and may include testing of the entire or portions of the population, random testing, rotational testing, mobile testing programs, and testing of categories of individuals at high risk of becoming infected or passing on infections. (4) Potential scale-up The Director shall consult with the industry and shall determine the maximum technical and economic capacity and shortest times that would be possible to scale up production and supplies of different methods of testing. (5) Determination of infection rates The Director shall implement an emergency serologic